share_log

Citigroup Initiates Coverage On Travere Therapeutics With Neutral Rating, Announces Price Target of $7

Benzinga ·  Nov 20, 2023 05:55

Citigroup analyst Carly Kenselaar initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Neutral rating and announces Price Target of $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment